81 related articles for article (PubMed ID: 32606420)
21. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.
Rossignol JF
J Infect Public Health; 2016; 9(3):227-30. PubMed ID: 27095301
[TBL] [Abstract][Full Text] [Related]
22. Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets.
Oh DY; Panozzo J; Vitesnik S; Farrukee R; Piedrafita D; Mosse J; Hurt AC
Antivir Ther; 2018; 23(4):295-306. PubMed ID: 28195559
[TBL] [Abstract][Full Text] [Related]
23. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.
Cinatl J; Morgenstern B; Bauer G; Chandra P; Rabenau H; Doerr HW
Lancet; 2003 Jun; 361(9374):2045-6. PubMed ID: 12814717
[TBL] [Abstract][Full Text] [Related]
24. Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication.
Zhang P; Liu X; Liu H; Wang W; Liu X; Li X; Wu X
Microb Pathog; 2018 Jan; 114():124-128. PubMed ID: 29170045
[TBL] [Abstract][Full Text] [Related]
25. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
26. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
Abbasi J
JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
[No Abstract] [Full Text] [Related]
27. The impact of co-infection of influenza A virus on the severity of Middle East Respiratory Syndrome Coronavirus.
Alfaraj SH; Al-Tawfiq JA; Alzahrani NA; Altwaijri TA; Memish ZA
J Infect; 2017 May; 74(5):521-523. PubMed ID: 28189714
[No Abstract] [Full Text] [Related]
28. Recent antiviral strategies against human coronavirus-related respiratory illnesses.
Golda A; Pyrc K
Curr Opin Pulm Med; 2008 May; 14(3):248-53. PubMed ID: 18427249
[TBL] [Abstract][Full Text] [Related]
29. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
30. Antiviral Action of Tryptanthrin Isolated from
Tsai YC; Lee CL; Yen HR; Chang YS; Lin YP; Huang SH; Lin CW
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32120929
[No Abstract] [Full Text] [Related]
31. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
[TBL] [Abstract][Full Text] [Related]
32. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
33. Molecular pharmacology of ciclesonide against SARS-CoV-2.
Kimura H; Kurusu H; Sada M; Kurai D; Murakami K; Kamitani W; Tomita H; Katayama K; Ryo A
J Allergy Clin Immunol; 2020 Aug; 146(2):330-331. PubMed ID: 32593491
[No Abstract] [Full Text] [Related]
34. Effective Chemicals against Novel Coronavirus (COVID-19) in China.
Liu W; Zhu HL; Duan Y
Curr Top Med Chem; 2020; 20(8):603-605. PubMed ID: 32133962
[No Abstract] [Full Text] [Related]
35. Fitness Barriers Limit Reversion of a Proofreading-Deficient Coronavirus.
Graepel KW; Agostini ML; Lu X; Sexton NR; Denison MR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341046
[TBL] [Abstract][Full Text] [Related]
36. Structural Biology Aids the Research of New Anti-COVID-19 Drugs.
Lu J; Liu X
Curr Org Synth; 2020; 17(3):162-163. PubMed ID: 32538717
[No Abstract] [Full Text] [Related]
37. Coronavirus reverse genetics by targeted RNA recombination.
Masters PS; Rottier PJ
Curr Top Microbiol Immunol; 2005; 287():133-59. PubMed ID: 15609511
[TBL] [Abstract][Full Text] [Related]
38. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target.
Yuan S; Chu H; Huang J; Zhao X; Ye ZW; Lai PM; Wen L; Cai JP; Mo Y; Cao J; Liang R; Poon VK; Sze KH; Zhou J; To KK; Chen Z; Chen H; Jin DY; Chan JF; Yuen KY
Sci Adv; 2020 Aug; 6(35):eaba7910. PubMed ID: 32923629
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
40. Repurposing host-based therapeutics to control coronavirus and influenza virus.
Li CC; Wang XJ; Wang HR
Drug Discov Today; 2019 Mar; 24(3):726-736. PubMed ID: 30711575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
